Pancreatic Cancer

An Insidious and Stubborn Foe

Pancreatic cancer is the third leading cause of cancer-related death in the United States. With a predicted five-year relative survival rate of 9%, pancreatic cancer continues to be clinically challenging due to its resistance to even the most aggressive combinations of surgery, chemotherapy, and radiotherapy. Because of indistinct symptoms and the absence of reliable diagnostic biomarkers, diagnoses are usually delayed and thus made when the disease is already advanced (which decreases five-year survival to less than 3%). Nevertheless, extensive research has highlighted the importance of several biomarkers and reagents that can significantly improve early detection.

 

Objectives of the webinar:

1. Anatomy and Biology of Pancreatic Cancer

2. Diagnostic Modalities, Biomarkers, and Clinical Features

3. Therapeutic Options and Future Directions

4. GeneTex’s Pancreatic Cancer Product Catalog